FDA has approved a brand name change for the antidepressant Brintellix (vortioxetine) to decrease the risk of prescribing and dispensing errors resulting from name confusion with the blood-thinning medicine Brilinta (ticagrelor). The new brand name of the drug will be Trintellix, and it is expected to be available starting in June 2016. No other changes will be made to the label or packaging, and the medicine is exactly the same. Trintellix tablets will look the same as the Brintellix tablets.
Read FDA Drug Safety Communication for additional details.
Related Pages
Vortioxetine (Trintellix®): Basic Information
Vortioxetine (Trintellix®): Efficacy
Vortioxetine (Trintellix®): Pharmacological effects
Vortioxetine (Trintellix®): Drug Interactions
Vortioxetine (Trintellix®): Side Effects
Vortioxetine (Trintellix®): An organized list of references
Antidepressants: Index and Links
Psychopharmacology: Index and Links
References
MedWatch: The FDA Safety Information and Adverse Event Reporting Program
Copyright 2016, Rajnish Mago, MD. All rights reserved. May not be reproduced in any form without express written permission.
Disclaimer: The content on this website is provided as general education for medical professionals. It is not intended or recommended for patients or other laypersons, or as a substitute for medical advice, diagnosis, or treatment. Patients must always consult a qualified health care professional regarding their diagnosis and treatment. Healthcare professionals should always check this website for the most recently updated information.
Leave a Reply